Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

NCT03532009 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

182

Enrollment

INDUSTRY

Sponsor class

Stopped Study stopped early due to the COVID-19 pandemic

Conditions

Heart Failure

Interventions

DRUG: Sodium Zirconium Cyclosilicate
DRUG: Placebo

Sponsor

AstraZeneca